Technical Analysis for SBPH - Spring Bank Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.15 4.55% 0.05
SBPH closed up 4.55 percent on Wednesday, February 19, 2020, on 37 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical SBPH trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 4.55%
Outside Day Range Expansion 4.55%
Wide Bands Range Expansion 4.55%
Down 3 Days in a Row Weakness 4.55%
Down 4 Days in a Row Weakness 4.55%
Oversold Stochastic Weakness 4.55%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that are design to target and modulate the activity of specific proteins implicated in various disease states. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops preclinical product candidates, such as SB 9400, SB 9941 and SB 9946 for RNA viral diseases. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Milford, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Disease Specialty Drugs Chronic Hepatitis B Virus Human Orthopneumovirus Preclinical Preclinical Product

Is SBPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.0
52 Week Low 1.0997
Average Volume 409,389
200-Day Moving Average 3.66
50-Day Moving Average 2.00
20-Day Moving Average 1.37
10-Day Moving Average 1.17
Average True Range 0.15
ADX 25.8
+DI 17.46
-DI 31.67
Chandelier Exit (Long, 3 ATRs ) 1.63
Chandelier Exit (Short, 3 ATRs ) 1.54
Upper Bollinger Band 1.98
Lower Bollinger Band 0.75
Percent B (%b) 0.32
BandWidth 89.54
MACD Line -0.23
MACD Signal Line -0.25
MACD Histogram 0.0293
Fundamentals Value
Market Cap 14.6 Million
Num Shares 12.7 Million
EPS -2.50
Price-to-Earnings (P/E) Ratio -0.46
Price-to-Sales 0.00
Price-to-Book 4.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.30
Resistance 3 (R3) 1.30 1.25 1.28
Resistance 2 (R2) 1.25 1.21 1.25 1.27
Resistance 1 (R1) 1.20 1.19 1.23 1.20 1.26
Pivot Point 1.15 1.15 1.16 1.15 1.15
Support 1 (S1) 1.10 1.11 1.13 1.10 1.04
Support 2 (S2) 1.05 1.09 1.05 1.03
Support 3 (S3) 1.00 1.05 1.03
Support 4 (S4) 1.00